Novel Rate-Area-Shape Modeling Approach To Quantify Bacterial Killing and Regrowth forIn VitroStatic Time-Kill Studies

The Future of Antibiotics and Resistance

(2013) Brad Spellberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1-Producing Enterobacteriaceae

(2012) Mahableshwar Albur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Pharmacodynamics of AZD5206 against Staphylococcus aureus

(2012) V. H. Tam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill

(2012) Gengrong Lin et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Application of Pharmacokinetic-Pharmacodynamic Modeling and the Justification of a Novel Fusidic Acid Dosing Regimen: Raising Lazarus From the Dead

(2011) Brian T. Tsuji et al.   CLINICAL INFECTIOUS DISEASES

Dosing of colistin—back to basic PK/PD

(2011) Phillip J Bergen et al.   CURRENT OPINION IN PHARMACOLOGY

Optimizing dosage to prevent emergence of resistance – lessons from in vitro models

(2011) Renu Singh et al.   CURRENT OPINION IN PHARMACOLOGY

In vitro time–kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin

(2011) Céline Vidaillac et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Evaluation of the pharmacokinetics–pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection

(2011) Olanrewaju O. Okusanya et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

(2011) Johan W. Mouton et al.   DRUG RESISTANCE UPDATES

In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore

(2011) Tze-Peng Lim et al.   PLoS One

Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B

(2011) Tze-Peng Lim et al.   PLoS One

Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia

(2009) Y. Harigaya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype

(2009) D. Begic et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Looming Global-Scale Failures and Missing Institutions

(2009) B. Walker et al.   SCIENCE

Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of Staphylococcus aureus Infection

(2008) A. P. MacGowan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus

(2008) B. T. Tsuji et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae

(2008) A. Poudyal et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY